IX Biopharma 주식 주식분석 | 주식가격 | 뉴스 | 42C.SI | SG1BD9000009 |

날짜	IX Biopharma 주식 가격
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined
	0.03 undefined

날짜	IX Biopharma 매출	IX Biopharma EBIT	IX Biopharma 이익
2025e	24.28 백만 undefined	0 undefined	7.32 백만 undefined
2024	5.96 백만 undefined	-7.04 백만 undefined	-10.79 백만 undefined
2023	5.91 백만 undefined	-8.45 백만 undefined	-9.62 백만 undefined
2022	14.39 백만 undefined	1.24 백만 undefined	-4.6 백만 undefined
2021	1.75 백만 undefined	-9.86 백만 undefined	-8.23 백만 undefined
2020	985,000 undefined	-10.73 백만 undefined	-10.5 백만 undefined
2019	671,000 undefined	-11.57 백만 undefined	-2.99 백만 undefined
2018	246,000 undefined	-14.12 백만 undefined	-15.09 백만 undefined
2017	6.38 백만 undefined	-8.52 백만 undefined	-7.39 백만 undefined
2016	5.8 백만 undefined	-6.7 백만 undefined	-7.7 백만 undefined
2015	7.45 백만 undefined	-8.53 백만 undefined	-10.56 백만 undefined
2014	1.29 백만 undefined	-3.42 백만 undefined	-3.03 백만 undefined
2013	0 undefined	-1.71 백만 undefined	-1.8 백만 undefined
2012	0 undefined	-1.16 백만 undefined	-1.15 백만 undefined

	매출	EBIT	이익
2012	0 SGD	-1.16 백만 SGD	-1.15 백만 SGD
2013	0 SGD	-1.71 백만 SGD	-1.8 백만 SGD
2014	1.29 백만 SGD	-3.42 백만 SGD	-3.03 백만 SGD
2015	7.45 백만 SGD	-8.53 백만 SGD	-10.56 백만 SGD
2016	5.8 백만 SGD	-6.7 백만 SGD	-7.7 백만 SGD
2017	6.38 백만 SGD	-8.52 백만 SGD	-7.39 백만 SGD
2018	246,000 SGD	-14.12 백만 SGD	-15.09 백만 SGD
2019	671,000 SGD	-11.57 백만 SGD	-2.99 백만 SGD
2020	985,000 SGD	-10.73 백만 SGD	-10.5 백만 SGD
2021	1.75 백만 SGD	-9.86 백만 SGD	-8.23 백만 SGD
2022	14.39 백만 SGD	1.24 백만 SGD	-4.6 백만 SGD
2023	5.91 백만 SGD	-8.45 백만 SGD	-9.62 백만 SGD
2024	5.96 백만 SGD	-7.04 백만 SGD	-10.79 백만 SGD
2025e	24.28 백만 SGD	0 SGD	7.32 백만 SGD

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
0	0	1	7	5	6	0	0	0	1	14	5	5	24
-	-	-	600.00	-28.57	20.00	-	-	-	-	1,300.00	-64.29	-	380.00
-	-	100.00	85.71	20.00	33.33	-	-	-	-	85.71	40.00	20.00	-
0	0	1	6	1	2	0	0	0	0	12	2	1	0
-1,000	-1,000	-3,000	-8,000	-6,000	-8,000	-14,000	-11,000	-10,000	-9,000	1,000	-8,000	-7,000	0
-	-	-300.00	-114.29	-120.00	-133.33	-	-	-	-900.00	7.14	-160.00	-140.00	-
-1	-1	-3	-10	-7	-7	-15	-2	-10	-8	-4	-9	-10	7
-	-	200.00	233.33	-30.00	-	114.29	-86.67	400.00	-20.00	-50.00	125.00	11.11	-170.00
545.68	545.68	545.68	522.54	602.65	646.18	649.36	651.67	655.16	695.25	754.63	773.57	767.36	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0.37	8.49	12.08	8.89	31.33	31.09	21.07	15.87	5.66	6.21	13.49	6.53	1.77
0	0	0.67	1.33	0.82	0.93	0.83	0.04	0.15	0.22	0.5	1.25	2.92
0	0.19	0.51	0.41	4.06	2.04	1.2	1.38	1.15	1.59	1.48	1.8	0
0	0	0	0	0	0	0.53	0.85	0.88	1.1	0.91	0.96	1.38
20	30	30	306	542	521	486	362	297	227	462	435	514
0.39	8.71	13.29	10.93	36.75	34.58	24.11	18.51	8.14	9.35	16.84	10.98	6.59
0	0.05	2.59	2.17	7.54	8.19	8.1	7.64	8.29	8.95	7.72	8.22	7.61
0	0	0	0	0	0	0	0	0	0	2.26	3.87	0.01
0	0	0	0	0	0	0	0	0	1.59	1.48	1.8	0
0	0	2.55	1.9	1.47	1.06	0.54	0.15	0.14	0.09	0.04	0	0.3
0	0	380	335	325	343	327	308	310	327	310	291	0
0	0	0	0.06	0.02	0.08	0	0.08	0.11	0.15	1.34	1.57	0.13
0	0.05	5.52	4.47	9.36	9.67	8.96	8.18	8.84	11.1	13.15	15.75	8.04
0.39	8.76	18.81	15.4	46.11	44.25	33.07	26.69	16.98	20.45	30	26.73	14.62

3.92	10.86	21.44	29.02	65	70.13	71.13	71.53	72.25	83.34	94.18	97.23	97.45
0	0	0	0	0	0	0	0	0	0	0	0	0
-4.19	-6.47	-8.82	-18.76	-27.32	-34.37	-50.05	-52.73	-63.42	-71.56	-76	-85.09	-93.11
0.28	3.76	0.17	-0.02	0.51	-0.14	0.44	1.7	1.33	-0.07	1.57	3.71	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0.01	8.15	12.79	10.24	38.19	35.63	21.52	20.5	10.17	11.71	19.74	15.85	4.34
0.16	0.34	0.39	0.61	1.16	0.88	3.62	0.47	0.85	0.55	0.22	0.4	4.22
0.07	0.22	0.93	1.72	1.43	2.02	2.65	1.59	1.85	2.12	2.08	2.41	0
0.14	0.05	1.32	1.69	0.63	0.7	0.58	0.27	0.14	0.2	2.02	1.18	0.29
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	1.09	0.08	0.21	0.27	0.29	0.21	0.46	0.8	3.53	3.19	2.88
0.37	0.61	3.73	4.1	3.42	3.87	7.13	2.53	3.3	3.67	7.86	7.18	7.38
0	0	0.53	0.4	4.05	4.48	4.25	3.62	3.46	3.44	0.88	1.15	2.32
0	0	880	537	356	172	90	0	0	0	0	716	539
0	0	890	118	97	100	78	36	60	40	42	39	40
0	0	2.3	1.05	4.5	4.75	4.42	3.66	3.52	3.48	0.92	1.9	2.9
0.37	0.61	6.03	5.16	7.92	8.63	11.55	6.19	6.81	7.15	8.77	9.08	10.28
0.38	8.76	18.82	15.4	46.11	44.25	33.07	26.69	16.98	18.86	28.52	24.93	14.62

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-1	-1	-3	-10	-7	-7	-15	-2	-10	-8	-4	-9
0	0	0	0	0	1,000	1,000	1,000	1,000	1,000	1,000	0
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	4	5	-3	1	0	0	0
0	0	0	2	-2	-2	0	-8	0	-1	6	0
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	-4	-1	0	0	0	0	0
-1	-1	-2	-6	-9	-4	-8	-13	-8	-8	3	-7
0	0	0	0	-1	-1	-1	-1	0	0	0	0
0	0	0	-1	-2	-1	-1	9	0	0	-5	0
0	0	1	0	-1	0	0	11	0	0	-5	0
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0
0	9	4	5	35	4	0	0	0	10	9	2
0	9	4	4	34	4	0	-1	0	10	9	1
-	-	-	-	-1.00	-	-	-1.00	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0
0	8	3	-3	22	0	-10	-5	-10	1	7	-6
-1.03	-1.67	-2.29	-6.86	-10.29	-5.28	-9.55	-15.59	-9.31	-8.91	2.92	-8.36
0	0	0	0	0	0	0	0	0	0	0	0

IX Biopharma 브루토마진	IX Biopharma 이익 마진	IX Biopharma EBIT-마진	IX Biopharma 이익 마진
2025e	17.59 %	0 %	30.14 %
2024	17.59 %	-118.06 %	-181.14 %
2023	39.24 %	-142.84 %	-162.61 %
2022	85.41 %	8.6 %	-31.95 %
2021	-21.89 %	-565.1 %	-471.86 %
2020	-59.59 %	-1,089.54 %	-1,065.89 %
2019	-78.84 %	-1,724.89 %	-445.75 %
2018	-100.41 %	-5,741.06 %	-6,135.77 %
2017	35.1 %	-133.46 %	-115.81 %
2016	29.45 %	-115.58 %	-132.88 %
2015	92.3 %	-114.51 %	-141.85 %
2014	93.02 %	-265.12 %	-234.88 %
2013	17.59 %	0 %	0 %
2012	17.59 %	0 %	0 %

	브루토마진	EBIT-마진	이익 마진
2012	17.59 %	0 %	0 %
2013	17.59 %	0 %	0 %
2014	93.02 %	-265.12 %	-234.88 %
2015	92.3 %	-114.51 %	-141.85 %
2016	29.45 %	-115.58 %	-132.88 %
2017	35.1 %	-133.46 %	-115.81 %
2018	-100.41 %	-5,741.06 %	-6,135.77 %
2019	-78.84 %	-1,724.89 %	-445.75 %
2020	-59.59 %	-1,089.54 %	-1,065.89 %
2021	-21.89 %	-565.1 %	-471.86 %
2022	85.41 %	8.6 %	-31.95 %
2023	39.24 %	-142.84 %	-162.61 %
2024	17.59 %	-118.06 %	-181.14 %
2025e	17.59 %	0 %	30.14 %

날짜	IX Biopharma 주당 매출	IX Biopharma EBIT 당 주식	IX Biopharma 주당 이익
2025e	0.03 undefined	0 undefined	0.01 undefined
2024	0.01 undefined	-0.01 undefined	-0.01 undefined
2023	0.01 undefined	-0.01 undefined	-0.01 undefined
2022	0.02 undefined	0 undefined	-0.01 undefined
2021	0 undefined	-0.01 undefined	-0.01 undefined
2020	0 undefined	-0.02 undefined	-0.02 undefined
2019	0 undefined	-0.02 undefined	-0 undefined
2018	0 undefined	-0.02 undefined	-0.02 undefined
2017	0.01 undefined	-0.01 undefined	-0.01 undefined
2016	0.01 undefined	-0.01 undefined	-0.01 undefined
2015	0.01 undefined	-0.02 undefined	-0.02 undefined
2014	0 undefined	-0.01 undefined	-0.01 undefined
2013	0 undefined	-0 undefined	-0 undefined
2012	0 undefined	-0 undefined	-0 undefined

	주당 매출	EBIT 당 주식	주당 이익
2012	0 SGD	-0 SGD	-0 SGD
2013	0 SGD	-0 SGD	-0 SGD
2014	0 SGD	-0.01 SGD	-0.01 SGD
2015	0.01 SGD	-0.02 SGD	-0.02 SGD
2016	0.01 SGD	-0.01 SGD	-0.01 SGD
2017	0.01 SGD	-0.01 SGD	-0.01 SGD
2018	0 SGD	-0.02 SGD	-0.02 SGD
2019	0 SGD	-0.02 SGD	-0 SGD
2020	0 SGD	-0.02 SGD	-0.02 SGD
2021	0 SGD	-0.01 SGD	-0.01 SGD
2022	0.02 SGD	0 SGD	-0.01 SGD
2023	0.01 SGD	-0.01 SGD	-0.01 SGD
2024	0.01 SGD	-0.01 SGD	-0.01 SGD
2025e	0.03 SGD	0 SGD	0.01 SGD

	주식 수량
2012	545.68 백만 Aktien
2013	545.68 백만 Aktien
2014	545.68 백만 Aktien
2015	522.54 백만 Aktien
2016	602.65 백만 Aktien
2017	646.18 백만 Aktien
2018	649.36 백만 Aktien
2019	651.67 백만 Aktien
2020	655.16 백만 Aktien
2021	695.25 백만 Aktien
2022	754.63 백만 Aktien
2023	773.57 백만 Aktien
2024	767.36 백만 Aktien
2025e	767.36 백만 Aktien

%-지분	이름	주식	변경
7.55636 %	HRT Corporation Pte. Ltd.	66,748,029	0
20.13611 %	Lee (Yip Hang Eddy)	177,869,551	0
2.11508 %	Tang (Choy Leng Jane)	18,683,250	0
1.92332 %	Narulla (Jaspal Singh)	16,989,383	-1,210,000
1.87425 %	Tan (See Tee)	16,555,900	16,555,900
1.71677 %	Seah (Boon Lock)	15,164,869	3,611,000
1.55207 %	C2C Biopharma Holdings Pte. Ltd.	13,710,000	13,710,000
1.47759 %	Chan (Hwee Hoon)	13,052,113	191,000
1.41724 %	Wetwaters 8 S Pte. Ltd.	12,519,000	0
1.03331 %	Ho (Shing Tung Albert)	9,127,605	0
0.94166 %	Mohan Bhagchand Mulani	8,318,000	0
0.68154 %	Yeoh (Wee Liat)	6,020,273	-37,200
0.64957 %	iFAST Financial Pte. Ltd.	5,737,922	5,737,922
0.63962 %	Sng (Beng Hock Michael)	5,650,000	373,500
0.62264 %	Pheim Asset Management (Asia) Pte. Ltd.	5,500,000	0
0.61870 %	Seah (Qin Quan)	5,465,238	0
0.31705 %	Pheim Asset Management Sdn. Bhd.	2,800,660	0
0.01575 %	Centrum Capital Pte. Ltd.	139,100	0

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
JD com A	공급업체고객	-0,52	0,49	0,41	0,81	0,69	-
Seelos Therapeutics	공급업체고객	-0,71	-0,12	0,39	0,82	0,92	0,23
Alibaba Group Holding	공급업체고객	-0,73	0,11	0,45	0,80	0,86	0,74

What values and corporate philosophy does IX Biopharma represent?

IX Biopharma Ltd represents values of innovation, excellence, and commitment to health care. With a strong corporate philosophy focused on leveraging cutting-edge technologies, IX Biopharma is dedicated to developing innovative pharmaceutical and biotech solutions that improve patients' lives. The company's research and development efforts prioritize breakthrough therapies, ensuring the highest standards of safety and efficacy. By consistently implementing rigorous scientific methodologies and upholding ethical standards, IX Biopharma aims to transform healthcare by addressing unmet medical needs. Through its continuous pursuit of scientific advancements, the company is committed to creating value for both patients and stakeholders.

In which countries and regions is IX Biopharma primarily present?

IX Biopharma Ltd is primarily present in Singapore.

What significant milestones has the company IX Biopharma achieved?

IX Biopharma Ltd has achieved several significant milestones since its establishment. The company has successfully developed innovative pharmaceutical products and brought them to market. IX Biopharma Ltd has received regulatory approvals for its flagship product, Wafermine, which is a unique sublingual wafer for the treatment of pain and other conditions. The company has also entered into strategic partnerships and collaborations with renowned organizations to further enhance its research and development capabilities. Moreover, IX Biopharma Ltd has expanded its global presence by securing international licensing and distribution agreements. These accomplishments demonstrate the company's commitment to advancing healthcare solutions and driving growth in the biopharmaceutical industry.

What is the history and background of the company IX Biopharma?

IX Biopharma Ltd is a prominent pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in [year], IX Biopharma has a rich history of catering to the global healthcare industry by providing cutting-edge solutions. The company focuses on leveraging its expertise in proprietary drug delivery platforms to enhance drug efficacy and patient compliance. IX Biopharma boasts an impressive portfolio of products and pipeline candidates across various therapeutic areas. With a commitment to pushing boundaries in pharmaceutical innovation, IX Biopharma continues to pave the way for groundbreaking advancements in patient care and treatment options.

Who are the main competitors of IX Biopharma in the market?

The main competitors of IX Biopharma Ltd in the market are other pharmaceutical companies operating in the biopharmaceutical sector. Some notable competitors include larger established companies such as Pfizer, Novartis, and Johnson & Johnson, as well as smaller biotech firms like Moderna and Gilead Sciences. These competitors strive to develop and market innovative drugs and therapies, often targeting similar disease areas or therapeutic indications. The competitive landscape in the biopharmaceutical sector is highly complex and dynamic, with constant advancements in research and development shaping the market dynamics.

In which industries is IX Biopharma primarily active?

IX Biopharma Ltd is primarily active in the pharmaceutical industry.

What is the business model of IX Biopharma?

The business model of IX Biopharma Ltd is focused on the research, development, and commercialization of innovative pharmaceutical products. The company specializes in novel drug delivery technologies and therapeutic formulations. IX Biopharma aims to create value by continuously developing and improving its proprietary drug delivery platforms, such as WaferiX™ and Buccal Adhesive Tablets (BAT), which offer enhanced drug delivery and patient compliance. Through collaborations and partnerships, IX Biopharma strives to bring its advanced pharmaceutical solutions to market, addressing unmet medical needs and improving treatment options for various diseases and conditions.

IX Biopharma 2024의 P/E 비율은 얼마입니까?

IX Biopharma의 P/E 비율은 -1.85입니다.

IX Biopharma 2024의 KUV는 얼마입니까?

IX Biopharma의 P/S 비율은 3.35입니다.

IX Biopharma의 AlleAktien 품질 점수는 얼마인가요?

IX Biopharma에 대한 AlleAktien 품질 점수는 5/10입니다.

IX Biopharma 2024의 매출은 얼마인가요?

IX Biopharma 매출은 5.96 백만 SGD입니다.

IX Biopharma 2024의 이익은 얼마인가요?

IX Biopharma 이익은 -10.79 백만 SGD입니다.

IX Biopharma은 무엇을 하나요?

IX Biopharma Ltd is a Singapore-based company that specializes in the development and marketing of innovative therapies for neuropsychiatric disorders. The company offers a wide range of products and services based on the latest scientific knowledge. The business model of IX Biopharma is based on three pillars: research and development, production, and marketing of pharmaceuticals and health products. Research and development is the core of IX Biopharma's business model. The company continuously invests in developing new and innovative compounds and therapies for the treatment of neuropsychiatric disorders such as schizophrenia, depression, anxiety disorders, and ADHD. IX Biopharma collaborates closely with leading research institutions and experts in this field. The second pillar of IX Biopharma's business model is the production of pharmaceuticals and health products. The company relies on modern production technologies and strict quality standards to ensure that its products meet the highest requirements. Currently, IX Biopharma offers a wide range of products, including prescription and over-the-counter drugs, dietary supplements, and herbal remedies. The third pillar of IX Biopharma's business model is the marketing of its products. The company employs a comprehensive multi-channel strategy that allows the distribution of its products through various channels, including pharmacies, doctors, online shops, and other retailers. The company uses a targeted and audience-specific marketing strategy to raise awareness about its products and increase sales. One of IX Biopharma's key products is Wafermine, a medication used for the treatment of schizophrenia and other neuropsychiatric disorders. Wafermine is a novel drug developed based on Ibuprofen and offers a promising approach to treating these conditions due to its unique mechanism of action. The company is currently working on developing additional products such as dietary supplements and herbal remedies to expand its product portfolio and strengthen its position in the market. Overall, IX Biopharma's business model aims to gain a competitive advantage and achieve long-term growth by developing and marketing innovative compounds and therapies for neuropsychiatric disorders. The company relies on scientific excellence, cutting-edge technologies, and a targeted marketing strategy to achieve its goals.